Company / PP&E (Net)
Nurix Therapeutics, Inc. PP&E (Net) History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$22.5M
FY2025
5-year range
$11.3M / $22.5M
FY2021-FY2025
Trend
+26.7%
vs FY2024
Sector context
#76 of 193
Health Care
What the data says
At $22M, Nurix Therapeutics, Inc.'s pp&e (net) ranks #76 of 193 in the Health Care sector. Improved from $17M to $22M over the past 2 years.
Based on SEC 10-K filings.
$22M in FY2025 with a 5-year CAGR of +27.5%.
Improved from $17M to $22M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +9.4%
- 5-Year CAGR
- +27.5%
- 10-Year CAGR
- -
Sector benchmark
#76 of 193 in Health CareTop 39% of 193This company $22.5M Sector average $777.6M
▼
-97.1% below sector average
Key checks
Key Insights
- 5-year CAGR of +27.5%, indicating consistent growth.
- In FY2025, pp&e (net) increased 26.7% year-over-year.
- Ranks #76 out of 193 companies in the Health Care sector.
- Lowest pp&e (net) in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score -0.35 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $22.5M | +26.7% |
| FY2024 | $17.8M | +5.6% |
| FY2023 | $16.8M | -2.1% |
| FY2022 | $17.2M | +51.3% |
| FY2021 | $11.3M | +70.0% |
| FY2020 | $6.7M | +72.4% |
| FY2019 | $3.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026